A new publication dated August 6, 2026 examines stigmasterol in relation to central precocious puberty. The study, titled "Stigmasterol alleviates central precocious puberty by targeting the IGF-1/PI3K/Akt/mTOR signaling pathway and modulating the Kisspeptin/GnRH axis," appeared in Biochimica et Biophysica Acta, Molecular Basis of Disease.
The publication addresses the IGF-1/PI3K/Akt/mTOR signaling pathway and its connection to the Kisspeptin/GnRH axis in the context of central precocious puberty. Kisspeptin, referenced in the study title, remains classified as an unapproved research compound. This brief reports only the existence and bibliographic details of the publication as provided.
No findings, results, or conclusions from the study are summarized here. Readers interested in the full scope of the research, including methodology and outcomes, should consult the original publication directly through the linked source. For general background on kisspeptin and its role in research contexts, readers can refer to the compound overview.